Mantle cell lymphoma: a retrospective study on 27 patients. Clinical features and natural history

被引:0
|
作者
Bertini, M
Rus, C
Freilone, R
Botto, B
Calvi, R
Novero, D
Orsucci, L
Vitolo, U
Palestro, G
Resegotti, L
机构
[1] Azienda Osped S Giovanni Battista, Div Ematol, I-10126 Turin, Italy
[2] Univ Turin, Serv Anat Patol 2, Turin, Italy
关键词
mantle cell lymphoma; chemotherapy;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objective. Mantle cell lymphoma (MCL) is a separate histological and clinical entity recently recognized in the new revised European-American Lymphoma Classification. Little information exists regarding its therapy. We report the results of a retrospective study of 27 patients affected by MCL evaluating the clinical characteristics and the results of different therapeutical options used during the period of observation. Design and Methods. From 1983 to 1993, we observed 27 patients affected by MCL according to the criteria proposed by European Lymphoma Task Force in a revision of 55 cases classified as NHL E according to Working Formulation (WF) criteria. We analyzed the clinical characteristics, the prognostic factors and the O.S. of these patients. Results. The clinical characteristics of our patients (pts) are similar to those observed in other series: male prevalence, median age 62 years, B symptoms in 9 cases, P.S. > 2 in 11 cases, 3 pts were in stage I and II, 4 in stage III, 20 in stage IV; 18 pts had a bone marrow involvement, 13 pts had spleen enlargement and 14 had extranodal localization; 8 pts had bulky tumor and 5 had LDH above normal. The On rate was 51,8%, the median O.S. was 43 months, and DFS was 18 months; the pts without bulky disease and with localized disease had a better On rate. The inclusion of an anthracycline in the regimen did not affect the results. Interpretation and Conclusions. Our results were not divergent from those present in literature. The mantle cell lymphoma Is an incurable and highly aggressive disease. Autologous bone marrow transplantation as support of high dose chemotherapy or allogenic bone marrow transplantation may be a chance for some patients, but not for the majority of patients, which are older than 65 years. Studies of a larger series and different therapeutical approaches, ie using biological modifiers in association or as maintenance after chemotherapy are essential. (C) 1998, Ferrata Storti Foundation.
引用
收藏
页码:312 / 316
页数:5
相关论文
共 50 条
  • [31] Gastrointestinal tract NK/t cell lymphoma: Clinical features, management, and prognosis of 47 patients.
    Jiang, Ming
    Zou, Li Qun
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] Outcome of young patients with blastoid variant mantle cell lymphoma: An analysis of 138 patients.
    Gerson, James
    Handorf, Elizabeth A.
    Barta, Stefan K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [33] Mantle Cell Lymphoma Prognostic Index and proliferative activity are strong prognostic markers in clinical practice: A retrospective study on 235 patients of the Czech Lymphoma Study Group
    Boudova, L.
    Vesela, P.
    Salek, D.
    Vokurka, S.
    Moulis, M.
    Kodet, R.
    Velenska, Z.
    Stritesky, J.
    Vernerova, Z.
    Trneny, M.
    Michal, M.
    VIRCHOWS ARCHIV, 2012, 461 : S20 - S20
  • [34] Rituximab/bendamustine/cytarabine for transplant-eligible patients with mantle cell lymphoma: A retrospective study
    Shimizu, Yuki
    Kaji, Daisuke
    Watanabe, Otoya
    Yamaguchi, Kyosuke
    Kageyama, Kosei
    Taya, Yuki
    Nishida, Aya
    Ishiwata, Kazuya
    Takagi, Shinsuke
    Yamamoto, Hisashi
    Mori, Yuki-Asano
    Wake, Atsushi
    Uchida, Naoyuki
    Taniguchi, Shuichi
    Yamamoto, Go
    CANCER MEDICINE, 2023, 12 (11): : 12548 - 12552
  • [35] Clinical outcomes of ibrutinib in patients with relapsed or refractory mantle cell lymphoma: Korean multicenter, retrospective analysis
    Yi, J. H.
    Kim, W. S.
    Kim, S. J.
    Yoon, D. H.
    Suh, C.
    Chang, M. H.
    Yang, D. H.
    Jo, J-C.
    Hyun, S. Y.
    Eom, H-S.
    Lee, J-O.
    Kwon, J. H.
    Han, S. H.
    Lee, S-S.
    Kwak, J-Y.
    Kim, S. H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [36] Clinical Characteristics, Treatment and Outcome of Patients with Mantle Cell Lymphoma: A Large, Multicenter Retrospective Analysis in China
    Yang, Ping
    Liu, Shuozi
    Wang, Jing
    Zhang, Wei
    Liu, Hui
    Sun, Xiuhua
    Dong, Yujun
    Jing, Hongmei
    BLOOD, 2021, 138
  • [37] The number of additional chromosomal abnormalities found by CCA at diagnosis is a strong independent prognostic factor in patients with mantle cell lymphoma: Results of a retrospective study in 61 patients.
    Lionne-Huyghe, P
    Depil, S
    Andrieux, J
    Gastinne, T
    Berthon, C
    Bauters, F
    Copin, MC
    Lai, JL
    Morschhauser, F
    BLOOD, 2003, 102 (11) : 888A - 888A
  • [38] Hairy cell leukemia:: Clinical features and treatment with cladribine.: A retrospective review of 21 patients.
    De Boeck, K
    Zachée, P
    Paridaens, K
    De Bock, R
    BLOOD, 1998, 92 (10) : 235B - 235B
  • [39] NEW PROGNOSTIC FACTORS IN MANTLE CELL LYMPHOMA: A MONOCENTRIC RETROSPECTIVE STUDY
    Signori, L.
    Pancani, F.
    Mannelli, L.
    Di Rocco, A.
    Zizza, M.
    Vergoni, F.
    Santi, R.
    Lucarelli, C.
    Romano, I.
    Mannarelli, C.
    Puccini, B.
    Scappini, B.
    Farcomeni, A.
    Bosi, A.
    HAEMATOLOGICA, 2020, 105 : S100 - S100
  • [40] Unusual Presentation of Pleomorphic Mantle Cell Lymphoma and Comparative Study of Clinical Features With Previously Published Cases
    Achebe, Ifeoma
    Nzewi, Chukwuemeka
    Nwachukwu, Chioma
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S519 - S519